Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Top 10 Drugs Of 2020: #2 Keytruda

The Only Way Is Up

You may also be interested in...



Merck & Co.’s Keytruda Stakes Another Adjuvant Flag, In RCC

Adjuvant renal cell carcinoma is a potentially lucrative indication for any checkpoint inhibitor; Merck & Co. flagship Keytruda is the first to demonstrate benefit in a Phase III study, although rivals are in pursuit.

The Value And Challenge Of Focus In Pharma

A 10-year review of the top 20 biopharmaceutical companies by revenue found that portfolio focus, not therapeutic area diversity, delivered the strongest growth rates.

Davis To Shepherd Merck & Co. Toward The Post-Keytruda Era, As Frazier Exits

Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144170

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel